Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Arcturus Therapeutics logo — A messenger RNA medicines company focused on the development...

Arcturus Therapeutics

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics

Founded 2013 United States San Diego, United States 155 employees Grant Total: $489.58M Biotechnology, Health Care +1

General Information

Company Name Arcturus Therapeutics
Founded Year 2013
Location United States San Diego, United States +1
Employees 155
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

Get notified when Arcturus Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines company based in San Diego, California. Founded in 2013, it operates in the Biotechnology and Health Care industries. Arcturus specializes in the development of mRNA medicines and vaccines, utilizing innovative technologies including LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA). The company has garnered attention for its ongoing global collaboration with CSL Seqirus for innovative mRNA vaccines, and its joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus has a diverse pipeline including RNA therapeutic candidates aimed at treating ornithine transcarbamylase deficiency and cystic fibrosis, along with partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The company's technologies are supported by an extensive patent portfolio with patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. In its latest funding round, Arcturus Therapeutics secured a $9.00M Grant investment on 26 September 2023, with the Cystic Fibrosis Foundation participating as the investor. With its cutting-edge technology and diverse pipeline, Arcturus Therapeutics holds promise as a pioneering force in the field of mRNA therapeutics and vaccines.

Taxonomy: mRNA medicines, vaccines, LUNAR® lipid-mediated delivery, STARR® mRNA Technology, mRNA drug substance, drug product manufacturing, RNA therapeutic candidates, mRNA vaccine programs, ornithine transcarbamylase deficiency, cystic fibrosis, nucleic acid medicines, patent portfolio, clinical trials, drug development

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
26 Sep 2023
Grant •••••• 1
Investor
14 Aug 2023
Grant •••••• 1 •••• •••• 31 Aug 2022
Post-IPO Equity •••••• - 28 Jul 2020
Post-IPO Equity •••••• - 15 Apr 2020

View All 9 Funding Rounds

Arcturus Therapeutics Alternatives & Competitors

Arcturus Therapeutics vs
CureVac
CureVac Germany

We fight for human health - we are the RNA people

Acquired
678 employees
Compare Arcturus Therapeutics vs CureVac
Arcturus Therapeutics vs
Orion Therapeutics, Inc.
Orion Therapeutics, Inc. United States

Platform technology providing targeted delivery of RNA aimed at curing and preventing previously und...

7 employees
Biotechnology, Health Care
Arcturus Therapeutics vs
Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics, Inc. United States

Reimagine the Power of RNA

Series Unknown
13 employees
Biotechnology, Health Care
Compare Arcturus Therapeutics vs Elixirgen Therapeutics, Inc.
Also compare with: Arcturus Therapeutics vs Aquestive Therapeutics Aquestive Therapeutics

FAQ About Arcturus Therapeutics

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics
Arcturus Therapeutics was founded in 2013.
Arcturus Therapeutics is headquartered in San Diego, United States.
Arcturus Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Arcturus Therapeutics has approximately 155 employees.
Arcturus Therapeutics has completed 9 funding rounds, raising a total of $489.58M. The latest funding stage is Grant.
Top alternatives and competitors to Arcturus Therapeutics include CureVac, Orion Therapeutics, Inc., Elixirgen Therapeutics, Inc., Aquestive Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arcturus Therapeutics and CureVac are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Arcturus Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy